A novel P300 inhibitor reverses DUX4-mediated global histone H3 hyperacetylation, target gene expression, and cell death

DUX4 drives global histone H3 hyperacetylation; and a new P300 inhibitor, iP300w, blocks DUX4-mediated transcription and toxicity. Facioscapulohumeral muscular dystrophy (FSHD) results from mutations causing overexpression of the transcription factor, DUX4, which interacts with the histone acetyltransferases, EP300 and CBP. We describe the activity of a new spirocyclic EP300/CBP inhibitor, iP300w, which inhibits the cytotoxicity of the DUX4 protein and reverses the overexpression of most DUX4 target genes, in engineered cell lines and FSHD myoblasts, as well as in an FSHD animal model. In evaluating the effect of iP300w on global histone H3 acetylation, we discovered that DUX4 overexpression leads to a dramatic global increase in the total amount of acetylated histone H3. This unexpected effect requires the C-terminus of DUX4, is conserved with mouse Dux, and may facilitate zygotic genome activation. This global increase in histone H3 acetylation is reversed by iP300w, highlighting the central role of EP300 and CBP in the transcriptional mechanism underlying DUX4 cytotoxicity and the translational potential of blocking this interaction.

[1]  M. Kyba,et al.  Crystal Structure of the Double Homeodomain of DUX4 in Complex with DNA. , 2018, Cell reports.

[2]  S. Harper,et al.  AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD. , 2018, JCI insight.

[3]  M. Kyba,et al.  Low level DUX4 expression disrupts myogenesis through deregulation of myogenic gene expression , 2018, Scientific Reports.

[4]  R. Tawil,et al.  Facioscapulohumeral Muscular Dystrophy: Update on Pathogenesis and Future Treatments , 2018, Neurotherapeutics.

[5]  Peter L Jones,et al.  A cre-inducible DUX4 transgenic mouse model for investigating facioscapulohumeral muscular dystrophy , 2018, PloS one.

[6]  Jayme L. Dahlin,et al.  Assay interference and off-target liabilities of reported histone acetyltransferase inhibitors , 2017, Nature Communications.

[7]  M. Kyba,et al.  The DUX4 homeodomains mediate inhibition of myogenesis and are functionally exchangeable with the Pax7 homeodomain , 2017, Journal of Cell Science.

[8]  Chunaram Choudhary,et al.  Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours , 2017, Nature.

[9]  Michael Kyba,et al.  Muscle pathology from stochastic low level DUX4 expression in an FSHD mouse model , 2017, Nature Communications.

[10]  M. Kyba,et al.  Muscle pathology from stochastic low level DUX4 expression in an FSHD mouse model , 2017, Nature Communications.

[11]  S. Tapscott,et al.  Conserved roles for murine DUX and human DUX4 in activating cleavage stage genes and MERVL/HERVL retrotransposons , 2017, Nature Genetics.

[12]  D. Trono,et al.  A family of double-homeodomain transcription factors regulates zygotic genome activation in placental mammals , 2017, Nature Genetics.

[13]  Stephen J. Tapscott,et al.  Conservation and innovation in the DUX4-family gene network , 2017, Nature Genetics.

[14]  M. Kyba,et al.  Transcriptional Inhibitors Identified in a 160,000-Compound Small-Molecule DUX4 Viability Screen , 2016, Journal of biomolecular screening.

[15]  Michael Kyba,et al.  DUX4 recruits p300/CBP through its C-terminus and induces global H3K27 acetylation changes , 2016, Nucleic acids research.

[16]  Julie M. Garlick,et al.  Characterizing the Covalent Targets of a Small Molecule Inhibitor of the Lysine Acetyltransferase P300. , 2016, ACS medicinal chemistry letters.

[17]  Daniel G. Miller,et al.  Endogenous DUX4 expression in FSHD myotubes is sufficient to cause cell death and disrupts RNA splicing and cell migration pathways. , 2015, Human molecular genetics.

[18]  Steven L Salzberg,et al.  HISAT: a fast spliced aligner with low memory requirements , 2015, Nature Methods.

[19]  Zizhen Yao,et al.  DUX4-induced gene expression is the major molecular signature in FSHD skeletal muscle. , 2014, Human molecular genetics.

[20]  A. Verbeek,et al.  Population-based incidence and prevalence of facioscapulohumeral dystrophy , 2014, Neurology.

[21]  Björn Usadel,et al.  Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..

[22]  M. Kyba,et al.  High-throughput screening identifies inhibitors of DUX4-induced myoblast toxicity , 2014, Skeletal Muscle.

[23]  Wei Shi,et al.  featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..

[24]  Daniel G. Miller,et al.  Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2 , 2012, Nature Genetics.

[25]  Elisa Negroni,et al.  Generation of isogenic D4Z4 contracted and noncontracted immortal muscle cell clones from a mosaic patient: a cellular model for FSHD. , 2012, The American journal of pathology.

[26]  Daniel G. Miller,et al.  A Unifying Genetic Model for Facioscapulohumeral Muscular Dystrophy , 2010, Science.

[27]  Ruben Abagyan,et al.  Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. , 2010, Chemistry & biology.

[28]  K. Tsuchida,et al.  Mesenchymal progenitors distinct from satellite cells contribute to ectopic fat cell formation in skeletal muscle , 2010, Nature Cell Biology.

[29]  Michael A. Rudnicki,et al.  Muscle injury activates resident fibro/adipogenic progenitors that facilitate myogenesis , 2010, Nature Cell Biology.

[30]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[31]  Michael Kyba,et al.  Biphasic Myopathic Phenotype of Mouse DUX, an ORF within Conserved FSHD-Related Repeats , 2009, PloS one.

[32]  Elaine Dzierzak,et al.  Runx1 is required for the endothelial to hematopoietic cell transition but not thereafter , 2009, Nature.

[33]  M. Kyba,et al.  An isogenetic myoblast expression screen identifies DUX4‐mediated FSHD‐associated molecular pathologies , 2008, The EMBO journal.

[34]  J. Shay,et al.  Cellular senescence in human myoblasts is overcome by human telomerase reverse transcriptase and cyclin‐dependent kinase 4: consequences in aging muscle and therapeutic strategies for muscular dystrophies , 2007, Aging cell.

[35]  J. Hewitt,et al.  Evolutionary conservation of a coding function for D4Z4, the tandem DNA repeat mutated in facioscapulohumeral muscular dystrophy. , 2007, American journal of human genetics.

[36]  A. Rosa,et al.  The DUX4 gene at the FSHD1A locus encodes a pro-apoptotic protein , 2007, Neuromuscular Disorders.

[37]  G. V. Ommen,et al.  Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy , 2003, Nature Genetics.

[38]  H. Ding,et al.  Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element. , 1999, Gene.

[39]  J E Hewitt,et al.  FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit. , 1993, Human molecular genetics.